Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined the dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations. DTG dissociates slowly from a wild-type IN-DNA complex at 37°C with an off-rate of 2.7 × 10 −6 s −1 and a dissociative half-life ( t 1/2 ) of 71 h, significantly longer than the half-lives for RAL (8.8 h) and ELV (2.7 h). Prolonged binding ( t 1/2 , at least 5 h) was observed for DTG with IN-DNA complexes containing E92, Y143, Q148, and N155 substitutions. The addition of a second substitution to either Q148 or N155 typically resulted in an increase in the off-rate compared to that with the single substitution. For all of the IN substitutions tested, the off-rate of DTG from IN-DNA complexes was significantly slower (from 5 to 40 times slower) than the off-rate of RAL or ELV. These data are consistent with the potential for DTG to have a higher genetic barrier to resistance, provide evidence that the INI off-rate may be an important component of the mechanism of INI resistance, and suggest that the slow dissociation of DTG may contribute to its distinctive resistance profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the dissociation half-times of dolutegravir and bictegravir from the wild-type HIV-1 intasome were reported to be ~100 and 160 h, respectively164,165.”
From Structure and function of retroviral integrase (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complete nucleotide sequence of the AIDS virus, HTLV-III
Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., et al. (1985) · Nature · doi:10.1038/313277a0 · Cited by 2,245 · cited 1×
“to make mutations in the wild type HIV-1 BH10 IN sequence (41).”
BackgroundDrug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Since INI binding generates nonreplicative forms of unintegrated viral cDNA, such as 2 long terminal repeats (27), there is less opportunity for the virus to undergo further rounds of replication which can generate additional mutations and thereby VOL.”
BackgroundRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691 · cited 1×
“21, 30, 40, 43, 47) and in clinical studies (5, 35, 36, 45).”
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509 · cited 2×
“For RAL, two main pathways for resistance involve signature mutations which are initially observed at amino acids Q148 and N155 and are almost invariably found with secondary mutations which may increase resistance and impact viral fitness and catalytic efficiency (5, 11, 18, 38, 40).”
BackgroundMarkowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408 · cited 1×
“21, 30, 40, 43, 47) and in clinical studies (5, 35, 36, 45).”
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Self-citationShimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010246107 · Cited by 305 · cited 1×
“The crystal structures of prototype foamy virus (PFV) IN in complex with DNA and RAL, ELV, (24), or DTG (25) and HIV-1 IN structural modeling studies (8, 9) provide insight into INI binding modes and how substitutions in the active site could impact INI binding.”
Background
Research works printed but not linked: 9
- 8. DeAnda F., Hattori K., Yoshinaga T., Kawasuji T., Underwood M. R. 2010. Structural models of HIV-1 integrase and DNA in complex with S/GSK1349572, raltegravir, or elvitegravir: structure-based rationale for INI resistance profiles. Antiviral Ther. 15(Suppl. 2):A73 [Google Scholar]
- 9. DeAnda F., et al. 2010. Structural rationale for slow S/GSK1349572 dissociation from wild type (WT) and raltegravir (RAL) resistant HIV-1 integrase (IN), abstr. H-1166. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother American Society for Microbiology, Washington, DC [Google Scholar]
- 10. DeJesus E., et al. 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137), abstr. TUPEB032. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention International AIDS Society, Geneva, Switzerland [Google Scholar]
- 13. Dicker I. B., et al. 2011. Longer integrase inhibitor dissociation half-lives induce persistent anti-HIV effects in cell culture, abstr. 521. Abstr. 18th Conf. Retrovir. Opportunistic Infect [Google Scholar]
- 23. Grobler J. A., et al. 2009. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors, abstr. O-10. Abstr. 10th Int. Workshop Clin. Pharmacol. HIV Ther. [Google Scholar]
- 28. Hluhanich R., et al. 2010. HIV integrase inhibitors (INIs) do not exert a post-antibiotic effect (PAE) despite slow dissociation from IN-DNA complexes in vitro, abstr. H-930. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother American Society for Microbiology, Washington, DC [Google Scholar]
- 29. Johns B., et al. 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile, abstr. 55. Abstr. 17th Conf. Retrovir. Opportunistic Infect. [Google Scholar]
- 46. Underwood M. R., Johns B., Sato A., Fujiwara T., Spreen W. 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, abstr. WEPEA098. Abstr. 5th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention International AIDS Society, Geneva, Switzerland [Google Scholar]
- 48. Yoshinaga T., Kanamori-Koyama M., Seki T., Sato A., Fujiwara T. 2010. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Antivir. Ther. 15(Suppl. 2):A12 [Google Scholar] Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)
Cited by
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
“Dolutegravir dissociates slowly from integrase-DNA complexes (t ½ =71 h, wildtype integrase) in vitro, 12 and has a 14-h plasma half-life in patients, supporting once-daily dosing without pharmacokinetic boosters.”
Self-citationHoffmann, C., Welz, T., Sabranski, M., Kolb, M. R. J., Wolf, E., Stellbrink, H., & Wyen, C. (2016) · HIV Medicine · doi:10.1111/hiv.12468 · Cited by 316
van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70290-0 · Cited by 301
Cottrell, M. L., Hadzic, T., & Kashuba, A. D. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0093-2 · Cited by 298
“7, 22 and 71, respectively, for wild-type complexes, and 37, 1160 and 1130 for complexes expressing a single Q148H mutation [8].”
BackgroundLesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Menéndez-Arias, L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.01.007 · Cited by 207
Hindmarsh, P., & Leis, J. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.4.836-843.1999 · Cited by 202
Current Perspectives on HIV-1 Antiretroviral Drug Resistance
Iyidogan, P., & Anderson, K. S. (2014) · Viruses · doi:10.3390/v6104095 · Cited by 196
“DTG is the latest approved drug against HIV infection and effective against the RAL and EVG resistant clinical isolates of HIV-1 including Q148K, N155H, Y143, and G140S/Q148H mutations [255].”
BackgroundInfluentialDolutegravir for the treatment of HIV
Katlama, C., & Murphy, R. L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.661713 · Cited by 189
“In vitro it appears that DTG has a distinct resistance profile from raltegravir and elvitegravir with a slower dissociation rate from wild-type and INI-resistant HIV-DNA complexes [32].”
BackgroundHIV drug resistance against strand transfer integrase inhibitors
Anstett, K., Brenner, B., Mesplede, T., & Wainberg, M. A. (2017) · Retrovirology · doi:10.1186/s12977-017-0360-7 · Cited by 176
“DTG has been shown to have a longer binding half-life to HIV IN than either RAL or EVG, which may help to explain why it maintains activity against most first-generation INSTI resistant variants [61].”
Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
Castellino, S., Moss, L., Wagner, D. S., Borland, J., Song, I. H., Chen, S., Lou, Y., Min, S., Goljer, I., Culp, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00292-13 · Cited by 172
“Furthermore, there is a potential for a higher barrier to resistance based on serial-passage experiments, dolutegravir activity against HIV-1 with single and multiple integrase mutation combinations (6), and prolonged binding to mutant integrase proteins in integrase-Mg(2) -DNA complexes (7).”
BackgroundDolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
Kandel, C., & Walmsley, S. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s84850 · Cited by 159
“The biologic plausibility for the incremental benefit of dolutegravir over raltegravir is the slower dissociation from the HIV-1 integrase-DNA complex and the reduced interindividual pharmacokinetic variability.(17,54) The VIKING trials assessed the utility of dolutegravir in populations with previous INSTI failure.”
Zhao, A., Crutchley, R. D., Guduru, R. C., Ton, K., Lam, T., & Min, A. (2022) · Retrovirology · doi:10.1186/s12977-022-00608-1 · Cited by 156
“Studies investigating the second generation INSTIs DTG and BIC have shown considerably longer dissociation half-lives from the wildtype intasome complex as well as from mutant intasomes commonly observed during treatment with first generation INSTIs [51, 52].”
Background3′‐Processing and strand transfer catalysed by retroviral integrase in crystallo
Hare, S., Maertens, G. N., & Cherepanov, P. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.118 · Cited by 153
“Recent biochemical data indicated a correlation between inhibitor activity against raltegravir-resistant HIV-1 variants and tighter binding to wild-type IN (slow off-rate) (Grobler et al , 2009; Hightower et al , 2011).”
Genetic barrier to resistance for dolutegravir.
Llibre, J. M., Pulido, F., García, F., Deltoro, M. G., Blanco, J. L., & Delgado, R. B. (2015) · PubMed · Cited by 152
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
Mesplède, T., Quashie, P. K., Osman, N., Han, Y., Singhroy, D. N., Lie, Y., Petropoulos, C. J., Huang, W., & Wainberg, M. A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-22 · Cited by 131
“The findings presented here may be related to the fact that DTG posesses a very long residency time on the HIV integrase enzyme [30].”
BackgroundRetroviral Integrase Proteins and HIV-1 DNA Integration
Krishnan, L., & Engelman, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.397760 · Cited by 97
“resistance changes correlate with significant increases in drug dissociation rates from these enzymes (71).”
BackgroundIntegrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2021) · Viruses · doi:10.3390/v13020205 · Cited by 132
the Montreal Primary HIV (PHI) Cohort Study Group, Oliveira, M., Ibanescu, R.-I., Anstett, K., Mésplède, T., Routy, J.-P., Robbins, M. A., & Brenner, B. G. (2018) · Retrovirology · doi:10.1186/s12977-018-0440-3 · Cited by 118
Role of Marine Natural Products in the Genesis of Antiviral Agents
Gogineni, V., Schinazi, R. F., & Hamann, M. T. (2015) · Chemical Reviews · doi:10.1021/cr4006318 · Cited by 127
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Abram, M. E., Hluhanich, R. M., Goodman, D. D., Andreatta, K. N., Margot, N., Ye, L., Niedziela‐Majka, A., Barnes, T. L., Novikov, N. Y., Chen, X., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02568-12 · Cited by 121
“Phenotypic susceptibilities of some IN mutant viruses against INSTIs (EVG and RAL) and NRTIs (FTC and TFV) were also determined in a multiple-round replication assay that measured cell viability, as previously described (12).”
BackgroundInfluentialDow, D. E., & Bartlett, J. A. (2014) · Infectious Diseases and Therapy · doi:10.1007/s40121-014-0029-7 · Cited by 119
“This slow dissociation may contribute to DTG’s high barrier to resistance and suggests that prolonged binding plays a role in its unique resistance profile [20, 21].”
Retroviral Integrase Structure and DNA Recombination Mechanism
Engelman, A., & Cherepanov, P. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0024-2014 · Cited by 94
“The capacity of a smallmolecule to trap theHIV-1 PIC in a long-lived inhibited state correlates with its antiviral activity, and extended dissociative half-time (td1/2) emerged as an important benchmark in INSTI development (210, 211).”
BackgroundInhibiting the HIV Integration Process: Past, Present, and the Future
Santo, R. D. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400674a · Cited by 112
Structural basis of second-generation HIV integrase inhibitor action and viral resistance
Cook, N. J., Li, W., Berta, D., Badaoui, M., Ballandras-Colas, A., Nans, A., Kotecha, A., Rosta, E., Engelman, A. N., & Cherepanov, P. (2020) · Science · doi:10.1126/science.aay4919 · Cited by 108
SeyedAlinaghi, S., Afsahi, A. M., Moradi, A., Parmoon, Z., Habibi, P., Mirzapour, P., Dashti, M., Ghasemzadeh, A., Karimi, E., Sanaati, F., et al. (2023) · AIDS Research and Therapy · doi:10.1186/s12981-023-00572-6 · Cited by 106
Malet, I., Subra, F., Charpentier, C., Collin, G., Descamps, D., Cálvez, V., Marcelin, A., & Delelis, O. (2017) · mBio · doi:10.1128/mbio.00922-17 · Cited by 105
Métifiot, M., Marchand, C., & Pommier, Y. G. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-405880-4.00003-2 · Cited by 105
“are about 3, 9, and 71 h for EVG, RAL, and DTG, respectively (Hightower et al., 2011).”
BackgroundTaiwo, B. O., Zheng, L., Stefanescu, A., Nyaku, A., Bezins, B., Wallis, C. L., Godfrey, C., Sax, P. E., Acosta, E., Haas, D., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1083 · Cited by 94
Kawasuji, T., Johns, B. A., Yoshida, H., Weatherhead, J. G., Akiyama, T., Taishi, T., Taoda, Y., Mikamiyama-Iwata, M., Murai, H., Kiyama, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301550c · Cited by 100
Self-citationMultifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
“Although analyses of mutant IN-viral complexes failed to identify a direct correlation between drug dissociation half-life and antiviral potency and resistance, HIV-1 was generally sensitive to INSTIs when compound dissociative half-life was greater than 4 h and resistant to inhibition when half-lives were less than 1…”
BackgroundNovel therapeutic strategies targeting HIV integrase
Quashie, P. K., Sloan, R. D., & Wainberg, M. A. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-34 · Cited by 74
“affinity of DTG for IN compared to RAL and EVG [72].”
BackgroundInfluentialDoyle, T., Dunn, D. T., Ceccherini‐Silberstein, F., de Mendoza, C., Garcia, F., Smit, E., Fearnhill, E., Marcelin, A., Martínez‐Picado, J., Kaiser, R., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv243 · Cited by 85
Emerging patterns and implications of HIV-1 integrase inhibitor resistance
Geretti, A. M., Armenia, D., & Ceccherini‐Silberstein, F. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835a1de7 · Cited by 83
“DTG also shows slower dissociation than RAL and EVG from both wild-type and mutated integrase–DNA complexes [30].”
BackgroundWares, M., Mesplède, T., Quashie, P. K., Osman, N., Han, Y., & Wainberg, M. A. (2014) · Retrovirology · doi:10.1186/1742-4690-11-7 · Cited by 77
“Despite the progress made in the past 30 years, however, significant issues with HIV treatment remain including those related to drug resistance, tolerability, ease of dosing, and adherence to therapy [1].”
BackgroundHIV integrase inhibitors: a new era in the treatment of HIV
Blanco, J. L., Whitlock, G. G., Milinkovic, A., & Moyle, G. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1044436 · Cited by 82
“Two aspects characterise the advantage of DTG over RAL and EVG regarding resistance: i) the different genotypic resistance patterns selected by first-generation INSTIs [28,33]; and ii) the apparently lower risk of selection of resistance following virological failure, hypothesised to be due to the prolonged binding to…”
BackgroundWainberg, M. A., & BRENNER, B. G. (2012) · Molecular Biology International · doi:10.1155/2012/256982 · Cited by 82
“It is also well known that INSTI Q148RHK resistance mutations that affect susceptibility to a novel INSTI, dolutegravir (DTG) in HIV-1 subtype B may not affect susceptibility of subtype C viruses or HIV-2 viruses and IN enzymes to the latter compound [84].”
BackgroundEvolution of HIV integrase resistance mutations
Quashie, P. K., Mesplède, T., & Wainberg, M. A. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835ba81c · Cited by 70
Garrido, C., Villacian, J., Zahonero, N., Pattery, T., Garcia, F., Gutierrez, F., Caballero, E., Van Houtte, M., Soriano, V., & de Mendoza, C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06170-11 · Cited by 64
Structural Biology of HIV Integrase Strand Transfer Inhibitors
Jozwik, I. K., Passos, D. O., & Lyumkis, D. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.003 · Cited by 78
Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV
Shah, B. M., Schafer, J. J., & DeSimone, J. A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1386 · Cited by 74
“An in vitro study demonstrated that dolutegravir has a higher genetic barrier to resistance than raltegravir and elvitegravir, which may be attributed to its significantly slower rate of dissociation (5–40 times slower) from the integrase enzyme in viruses that are either wild type or contain the N155, Q148, or Y143 m…”
BackgroundThe development of novel HIV integrase inhibitors and the problem of drug resistance
Wainberg, M. A., Mésplède, T., & Quashie, P. K. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.08.007 · Cited by 71
“Indeed, measurements of the RAL, EVG and DTG dissociation rate constants from an integraseDNA complex containing resistance mutations within integrase have been calculated and show a striking correlation between dissociation rate and levels of resistance [41,42].”
BackgroundResultInfluentialQuashie, P. K., Mésplède, T., Han, Y.-S., Veres, T., Osman, N., Hassounah, S. A., Sloan, R. D., Xu, H., & Wainberg, M. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01835-13 · Cited by 69
“This cross-resistance between RAL and EVG has necessitated the development of other INSTIs that possess higher barriers to resistance development as well as nonoverlapping resistance profiles.”
BackgroundInfluentialIntegrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
Brooks, K. M., Sherman, E. M., Egelund, E. F., Brotherton, A. L., Durham, S. H., Badowski, M. E., & Cluck, D. B. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2246 · Cited by 66
“The higher barrier of DTG to drug resistance, particularly in comparison with RAL and EVG, has been attributed in part to its long binding half-life to the integrase enzyme.(50) In the United States, currently the only FDC containing DTG is DTG/abacavir (ABC)/lamivudine (3TC) (Triumeq; ViiV Healthcare, Research Triang…”
BackgroundDolutegravir: clinical efficacy and role in HIV therapy
Fantauzzi, A., & Mezzaroma, I. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314530461 · Cited by 64
Deanda, F., Hightower, K. E., Nolte, R. T., Hattori, K., Yoshinaga, T., Kawasuji, T., & Underwood, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077448 · Cited by 64
Self-citationResistance to HIV integrase inhibitors
Mésplède, T., Quashie, P. K., & Wainberg, M. A. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328356db89 · Cited by 63
“4-fold, respectively, whereas the Y143 mutations had little effect [47].”
BackgroundResultNext-Generation Integrase Inhibitors: Where to After Raltegravir?
Karmon, S. L., & Markowitz, M. H. (2013) · Drugs · doi:10.1007/s40265-013-0015-5 · Cited by 58
Dolutegravir resistance mutations: lessons from monotherapy studies
Blanco, J. L., Marcelin, A., Katlama, C., & Martínez, E. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000453 · Cited by 56
Differences among HIV-1 subtypes in drug resistance against integrase inhibitors
Han, Y.-S., Mésplède, T., & Wainberg, M. A. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.06.047 · Cited by 55
Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults
McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-014-0256-y · Cited by 54
“Dolutegravir inhibits the replication of HIV-1 by binding to the two metal cations (Mg2?) within the catalytic active site of the integrase enzyme within the pre-integration complex, displacing the 30-terminal deoxyadenosine of the viral cDNA strand, and thereby preventing the transfer of the cDNA strand into the host…”
BackgroundInfluentialElvitegravir: a once-daily inhibitor of HIV-1 integrase
Wills, T. S., & Vega, V. R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.658914 · Cited by 53
Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection
Greig, S. L., & Deeks, E. D. (2015) · Drugs · doi:10.1007/s40265-015-0361-6 · Cited by 52
Boffito, M., Waters, L. J., Cahn, P. E., Paredes, R., Koteff, J. A., Wyk, J. A. V., Vincent, T., Demarest, J. F., Adkison, K. K., & Quercia, R. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0171 · Cited by 51
“Prolonged residence time at the active site may extend the duration of efficacy, contributing to a higher barrier to resistance.(27)”
BackgroundPostexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors
Dobard, C., Sharma, S., Parikh, U. M., West, R., Taylor, A., Martin, A. M., Pau, C., Hanson, D. L., Lipscomb, J. T., Smith, J. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007701 · Cited by 49
“The only clinically approved integrase inhibitors licensed for the treatment of HIV-infected persons are raltegravir (RAL), elvitegravir, and dolutegravir, all of which are strand transfer inhibitors (14, 19).”
BackgroundGriesel, R., Zhao, Y., Simmons, B., Omar, Z., Wiesner, L., Keene, C., Hill, A. M., Meintjes, G., & Maartens, G. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00081-4 · Cited by 48
Will drug resistance against dolutegravir in initial therapy ever occur?
Wainberg, M. A., & Han, Y.-S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00090 · Cited by 48
“Interestingly, combinations of R263K with primary resistance mutations for RAL and EVG at positions 143 and 148 resulted in vastly diminished enzymatic activity that may be incompatible with viral survival, which helps to explain why R263K has never been observed in the clinic together with primary RAL or EVGmutations…”
BackgroundInfluentialWhat if HIV were unable to develop resistance against a new therapeutic agent?
Wainberg, M. A., Mésplède, T., & Raffi, F. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-249 · Cited by 46
“Furthermore, biochemical results have shown that the ability of DTG to bind to the Integrase enzyme and remain associated with it is very long, that is, >36 hours, and that the R263K mutation only diminishes this level of binding by about 50% [14].”
BackgroundHIV Drug Resistance and the Advent of Integrase Inhibitors
Quashie, P. K., Mésplède, T., & Wainberg, M. A. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0305-1 · Cited by 46
Li, M., Oliveira Passos, D., Shan, Z., Smith, S. J., Sun, Q., Biswas, A., Choudhuri, I., Strutzenberg, T. S., Haldane, A., Deng, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg5953 · Cited by 39
Cento, V., & Perno, C. F. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.08.010 · Cited by 45
Seki, T., Suyama, A., Kawauchi, S., Miki, S., Wakasa-Morimoto, C., Akihisa, E., Nakahara, K., Kobayashi, M., Underwood, M., Sato, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04844-14 · Cited by 44
“DTG was designed to maintain activity against many INSTI-resistant mutants with single or multiple substitutions (20, 31–35), and this is consistent with biochemical and structural observations (36, 37).”
BackgroundResultSelf-citationDolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection
Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-019-01247-1 · Cited by 44
Park, T. E., Mohamed, A., Kalabalik, J., & Sharma, R. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1075393 · Cited by 42
“7 h for EVG in biochemical analyses using wild-type integrase DNA complexes, suggesting that longer duration of binding may contribute to higher barrier to resistance [68,69].”
MethodJain, S., & Mayer, K. H. (2014) · AIDS · doi:10.1097/qad.0000000000000301 · Cited by 42
“been recently US FDA-approved, and earlier studies have demonstrated that it is well tolerated and has a much higher barrier to resistance than raltegravir [58,59], which would be ideal for high-risk exposures to highly treatment-experienced individuals.”
BackgroundElvitegravir: A Review of Its Use in Adults with HIV-1 Infection
Deeks, E. D. (2014) · Drugs · doi:10.1007/s40265-014-0206-8 · Cited by 41
“8 and 71 h from wildtype integrase [25].”
BackgroundLiu, G., Luo, R., Zhou, Y., Zhang, X., Li, J., Yang, L., Zheng, Y., & Liu, H. (2016) · Molecules · doi:10.3390/molecules21091198 · Cited by 41
Hull, M., Shafran, S. D., Wong, A., Tseng, A. L.-I., Giguère, P., Barrett, L. L., Haider, S., Conway, B., Klein, M. B., & Cooper, C. (2016) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2016/4385643 · Cited by 40
Different Pathways Leading to Integrase Inhibitors Resistance
Thierry, E., Deprez, E., & Delelis, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02165 · Cited by 40
“Stability of the INSTI on the complex depends on the compounds studied, since different discordant half-life have been described for RAL, EVG, and DTG (8.8, 2.7, and 71 h, respectively) (Hightower et al., 2011).”
BackgroundInfluentialOnce-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.
Truong, W. R., Schafer, J. J., & Short, W. R. (2015) · PubMed · Cited by 40
Weller, S., Chen, S., Borland, J., Savina, P. M., Wynne, B., & Piscitelli, S. C. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000193 · Cited by 39
Jiang, J., Xi Tao, X. U., Guo, W., Su, J., Huang, J., Liang, B., Chen, H., Zang, N., Liao, Y., Ye, L., et al. (2016) · AIDS Research and Therapy · doi:10.1186/s12981-016-0115-x · Cited by 39
“Pharmacokinetic studies in people have also shown DTG has a long plasma half-life without the need for a booster [15].”
BackgroundIs Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
Mésplède, T., & Wainberg, M. A. (2014) · Viruses · doi:10.3390/v6093377 · Cited by 38
“fact that the ability of DTG to bind to the integrase enzyme is extremely long and exceeds by at least several fold the ability of either RAL or EVG to achieve similar binding [13].”
BackgroundUnderwood, M., Horton, J., Nangle, K., Hopking, J., Smith, K., Aboud, M., Wynne, B., Sievers, J., Stewart, E. L., & Wang, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01643-21 · Cited by 38
“Dissociation of INSTIs from integrase-DNA complexes was evaluated as previously described (35).”
BackgroundMethodInfluentialSelf-citationMoranguinho, I., Taveira, N., & Bártolo, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065905 · Cited by 37
Yang, L., Li, Q., Zhou, L.-B., & Chen, S. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.08.008 · Cited by 37
Neogi, U., Singh, K., Aralaguppe, S. G., Rogers, L. C., Njenda, D. T., Sarafianos, S. G., Hejdeman, B., & Sönnerborg, A. B. (2017) · AIDS · doi:10.1097/qad.0000000000001726 · Cited by 36
“The INSTIs DTG and BIC exhibit longer dissociation half-life in biochemical analyses of wild-type integrase/DNA complexes, resulting in a high genetic barrier to resistance [4,5].”
BackgroundLong Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
White, K. L., Osman, N., Cuadra-Foy, E., Brenner, B. G., Shivakumar, D., Campigotto, F., Tsiang, M., Morganelli, P. A., Novikov, N., Lazerwith, S. E., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02406-20 · Cited by 33
“Data sets were analyzed using a single exponential decay equation as previously published for INSTIs (3).”
BackgroundMethodResultInfluentialLozano, A. B., Chueca, N., de Salazar, A., Fernández-Fuertes, E., Collado, A., Fernández, J. M., Álvarez, M., & García, F. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104717 · Cited by 33
Munir, S., Thierry, E., Malet, I., Subra, F., Cálvez, V., Marcelin, A., Deprez, E., & Delelis, O. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku474 · Cited by 32
Obasa, A. E., Mikasi, S. G., Brado, D., Cloete, R. E. A., Singh, K., Neogi, U., & Jacobs, G. B. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00438 · Cited by 32
“…significant contributions to reducing the rates of morbidity and mortality in people living with HIV (PLHIV) and has led to better management of infection at an individual level, not only in high-income countries but also in low- and middle-income countries (Hightower et al., 2011; UNAIDS, 2017).”
BackgroundMight dolutegravir be part of a functional cure for HIV?
Wainberg, M. A., Han, Y.-S., & Mésplède, T. (2016) · Canadian Journal of Microbiology · doi:10.1139/cjm-2015-0725 · Cited by 32
“It is generally believed that the higher genetic barrier of DTG to resistance of HIV-1 is due to its slow dissociation rate from integrase–DNA complexes, in comparison with RAL and EVG (Hightower et al. 2011; Geretti et al. 2012; Osman et al. 2015; Wainberg and Han 2015).”
ResultDaryaee, F., Chang, A. T., Schiebel, J., Lü, Y., Zhang, Z., Kapilashrami, K., Walker, S. G., Kisker, C., Sotriffer, C., Fisher, S. L., et al. (2016) · Chemical Science · doi:10.1039/c6sc01000h · Cited by 31
Elliot, E. R., Chirwa, M., & Boffito, M. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000327 · Cited by 30
“There are three InSTIs licensed for HIV therapy in treatment naiı̈ve and experienced patients, these are RAL, elvitegravir (EVG) and dolutegravir (DTG).”
BackgroundInfluentialAdvances in the development of HIV integrase strand transfer inhibitors
Wang, Y., Gu, S., He, Q., & Fan, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113787 · Cited by 29
Moss, L., Wagner, D. S., Kanaoka, E., Olson, K. L., Yueh, Y. L., & Bowers, G. D. (2014) · Xenobiotica · doi:10.3109/00498254.2014.942409 · Cited by 28
“In vitro, dolutegravir has demonstrated low nanomolar potency with retained activity against integrase-resistant viral strains (Hightower et al., 2011; Kobayashi et al., 2011).”
BackgroundDesimmie, B. A., Demeulemeester, J., Suchaud, V., Taltynov, O., Billamboz, M., Lion, C. J., Bailly, F., Strelkov, S. V., Debyser, Z., Cotelle, P., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4000426 · Cited by 28
Canducci, F., Ceresola, E. R., Saita, D., Castagna, A., Gianotti, N., Underwood, M., Burioni, R., Lazzarin, A., & Clementi, M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt220 · Cited by 27
Self-citationTenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?
Clercq, E. D. (2012) · Medicinal Research Reviews · doi:10.1002/med.21267 · Cited by 27
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents
Dehority, W. N., Abadi, J., WIZNIA, A. A., & Viani, R. M. (2015) · Drugs · doi:10.1007/s40265-015-0446-2 · Cited by 26
“Dolutegravir dissociates from the integrase–DNA complex significantly slower than either raltegravir or elvitegravir, and possesses a half-life in plasma of approximately 15 h [75, 76].”
BackgroundDolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: Table 1.
Rokx, C., Schurink, C. A. M., Boucher, C. A., & Rijnders, B. J. A. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw011 · Cited by 26
Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
Engelman, K. D., & Engelman, A. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00157 · Cited by 27
Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors
Hikichi, Y., Grover, J. R., Schäfer, A., Mothes, W., & Freed, E. O. (2024) · Science Advances · doi:10.1126/sciadv.adn0042 · Cited by 26
“INSTIs exhibit very slow dissociation rates from the intasome ( 69 ), perhaps allowing intasomes to “soak up” INSTIs present in the cell, reducing their effective concentration.”
The preclinical discovery and development of dolutegravir for the treatment of HIV
Bailly, F., & Cotelle, P. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1064896 · Cited by 26
“To obtain a better understanding of INSTI dissociation kinetics and the relationship between dissociation rates and INSTI resistance, the dissociation rates of dolutegravir, raltegravir and elvitegravir with IN--DNA complexes (including IN mutant-resistant to raltegravir or elvitegravir) were measured (Table 3) [30].”
MethodHassounah, S. A., Mésplède, T., Quashie, P. K., Oliveira, M., Sandstrom, P. A., & Wainberg, M. A. (2014) · Journal of Virology · doi:10.1128/jvi.00947-14 · Cited by 26
Potential benefit of dolutegravir once daily: efficacy and safety
Mezzaroma, I., Fantauzzi, A., & Turriziani (2013) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s27765 · Cited by 26
“60 Furthermore, it has been demonstrated that dolutegravir has a longer dissociative half-life from the integrase enzyme than either raltegravir or elvitegravir.”
Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir
Krishna, R., Rizk, M. L., Larson, P., Schulz, V., Kesisoglou, F., & Pop, R. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.358 · Cited by 26
Mandal, S., Khandalavala, K., Pham, R. N., Bruck, P. T., Varghese, M., Kochvar, A. P., Monaco, A., Prathipati, P. K., Destache, C. J., & Shibata, A. (2017) · Polymers · doi:10.3390/polym9090423 · Cited by 25
Metadata
- Authors
- Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R.
- Affiliations
- GlaxoSmithKline, Research Triangle Park, North Carolina
- Shionogi (Japan) (JP)
- Corresponding author
- Underwood, Mark R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-10
- Volume
- 55
- Issue
- 10
- Pages
- 4552-4559
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3187001
- OpenAlex
- W2144255757
- Cited by
- 226
- References
- 39
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 11 · 2017: 19 · 2016: 16 · 2015: 32 · 2014: 27 · 2013: 23 · 2012: 17
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- dolutegravir, raltegravir, elvitegravir, HIV-1 integrase inhibitors, integrase inhibitor resistance, integrase-DNA complex, dissociation rate, dissociation rate constant, resistance mutations, resistance mechanisms
- MeSH terms
- Raltegravir Potassium, Dolutegravir, DNA, Viral, Genotype, Heterocyclic Compounds, 3-Ring, Mutation, Oxazines, Piperazines, Pyridones, Pyrrolidinones, Quinolones, HIV-1, DNA, Complementary, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.